Gemäß den neuesten Finanzberichten von Sarepta Therapeutics
hat das Unternehmen €0.98 Milliarde Euro an Nettovermögen.
Das Nettovermögen eines Unternehmens ist die Summe seiner Vermögenswerte abzüglich der Summe seiner Verbindlichkeiten.
Jahr | Nettovermögen | Veränderung |
---|---|---|
2024-12-31 | $€1.46 Mrd. | 88.86% |
2023-12-31 | $€0.77 Mrd. | 116.61% |
2022-12-31 | $€0.35 Mrd. | -56.21% |
2021-12-31 | $€0.81 Mrd. | 32.31% |
2020-12-31 | $€0.61 Mrd. | -15.2% |
2019-12-31 | $€0.73 Mrd. | -19.06% |
2018-12-31 | $€0.90 Mrd. | 37.18% |
2017-12-31 | $€0.65 Mrd. | 105.49% |
2016-12-31 | $€0.32 Mrd. | 83.87% |
2015-12-31 | $€0.17 Mrd. | -14.51% |
2014-12-31 | $€0.20 Mrd. | 13.76% |
2013-12-31 | $€0.17 Mrd. | 91.44% |
2012-12-31 | $€93.5 Mio. | 291.48% |
2011-12-31 | $€23.88 Mio. | -1227.75% |
2010-12-31 | $-€2.12 Millionen | -112.84% |
2009-12-31 | $€16.49 Mio. | 46.56% |
2008-12-31 | $€11.25 Mio. | -37.72% |
2007-12-31 | $€18.06 Mio. | -36.78% |
2006-12-31 | $€28.58 Mio. | -36.91% |
2005-12-31 | $€45.29 Mio. | 133.91% |
2004-12-31 | $€19.36 Mio. | -43.82% |
2003-12-31 | $€34.46 Mio. | 53.44% |
2002-12-31 | $€22.46 Mio. | -35.03% |
2001-12-31 | $€34.57 Mio. |
Unternehmen | Nettovermögen | DifferenzDiff. | Land |
---|---|---|---|
![]() Gilead Sciences GILD | €16.45 Mrd. | 1,569.53% | 🇺🇸 USA |
![]() Novavax NVAX | -€65.26 Millionen | -106.62% | 🇺🇸 USA |
![]() Avidity Biosciences RNA | €1.14 Mrd. | 16.28% | 🇺🇸 USA |
![]() BioCryst Pharmaceuticals
BCRX | -€0.39 Milliarde | -139.55% | 🇺🇸 USA |
![]() Alnylam Pharmaceuticals
ALNY | €99.58 Mio. | -89.90% | 🇺🇸 USA |
![]() PTC Therapeutics
PTCT | -€0.17 Milliarde | -116.26% | 🇺🇸 USA |
![]() Insmed INSM | €85.54 Mio. | -91.32% | 🇺🇸 USA |